According to our estimates, the number of clinical uses “DuraBeam®”, the artificial dura mater, has exceeded 3,000 cases this month.
TamaBio will continue to fulfill its product supply responsibilities under strict quality control. In addition, we will continue to work hard to develop innovative medical devices using regenerative medicine technology in order to establish new and effective treatment methods for more diseases.